Croma-Pharma unveils new toxin
As of January 25, aesthetic manufacturer Croma-Pharma has confirmed completion of the decentralised procedure for its new botulinum toxin.
As of January 25, aesthetic manufacturer Croma-Pharma has confirmed completion of the decentralised procedure for its new botulinum toxin.
Biopharmaceutical company Hugel America and aesthetic manufacturer Croma-Pharma has unveiled that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for letibotulinumtoxinA as a treatment for glabellar lines.
Pharmaceutical company Croma Pharma has rebranded its hyaluronic acid filler brand Princess to saypha.
We bring you the most up-to-date information for the Aesthetics community across a variety of media, including; news, webinars, podcasts, the Journal, reports, interviews and more!
aesthetics Journal
The Aesthetics Journal is the leading monthly publication for the medical aesthetics specialty. It is peer reviewed and spans an incredible volume of topics. Become a member today to receive the monthly print and digital Journal.
0203 096 1228
2nd Floor, Regal House, 70 London Road
Twickenham TW1 3QS, United Kingdom
© 2023 Easyfairs UK Ltd | Registered in England No. 05067979